Attack rates are shown across three clinical management phases: T0 (2016–September 2019, no prophylaxis), T1 (September 2019–April 2021, long-term prophylaxis with plasma-derived C1-INH), and T2 (April 2021–present, long-term prophylaxis with lanadelumab). Variations were −38.50% from T0 to T1 and −88.50% from T0 to T2. Data before T2 were retrospectively collected from the patient’s clinical history and medical records. C1-INH: C1 inhibitor.
Declarations
Author contributions
MBG: Conceptualization, Validation, Writing—review & editing. SS: Investigation, Writing—original draft. MR: Investigation, Writing—original draft. AZ: Validation, Writing—review & editing, Supervision. All authors read and approved the submitted version.
Conflicts of interest
Andrea Zanichelli received speaker/consultancy fees from and/or was a member of advisory boards for Astria Therapeutics, BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming, Pharvaris, Otsuka, and Takeda. The other authors declare no conflicts of interest.
Ethical approval
The study complies with the Declaration of Helsinki. Ethical approval is not required for a case report study according to the local ethics committee.
Consent to participate
Informed consent to participate in the study was obtained from the participant.
Consent to publication
Informed consent to publication was obtained from the participant.
Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Herz-Ruelas ME, Chavez-Alvarez S, Garza-Chapa JI, Ocampo-Candiani J, Cab-Morales VA, Kubelis-López DE. Netherton Syndrome: Case Report and Review of the Literature.Skin Appendage Disord. 2021;7:346–50. [DOI] [PubMed] [PMC]
Bitoun E, Chavanas S, Irvine AD, Lonie L, Bodemer C, Paradisi M, et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families.J Invest Dermatol. 2002;118:352–61. [DOI] [PubMed]
Akkurt ZM, Tuncel T, Ayhan E, Uçmak D, Uluca U, Uçak H. Rapid and easy diagnosis of Netherton syndrome with dermoscopy.J Cutan Med Surg. 2014;18:280–2. [DOI] [PubMed]
Costanzo G, Sambugaro G, Sartorio S, Zanichelli A, Firinu D. New drugs for the treatment of hereditary angioedema.Expert Opin Biol Ther. 2025;25:79–91. [DOI] [PubMed]
Caccia S, Suffritti C, Cicardi M. Pathophysiology of Hereditary Angioedema.Pediatr Allergy Immunol Pulmonol. 2014;27:159–63. [DOI] [PubMed] [PMC]
Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.Allergy. 2022;77:1961–90. [DOI] [PubMed]
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.Exp Dermatol. 2001;10:11–8. [DOI] [PubMed]
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis.Dermatology. 1993;186:23–31. [DOI] [PubMed]
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use.Clin Exp Dermatol. 1994;19:210–6. [DOI] [PubMed]
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.J Am Acad Dermatol. 2020;83:839–46. [DOI] [PubMed]
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus.Acta Derm Venereol. 2012;92:502–7. [DOI] [PubMed]
Puelles J, Fofana F, Rodriguez D, Silverberg JI, Wollenberg A, Barbosa CD, et al. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis.Br J Dermatol. 2022;186:285–94. [DOI] [PubMed] [PMC]
Martin-García C, Godoy E, Cabrera A, Cañueto J, Muñoz-Bellido FJ, Perez-Pazos J, et al. Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature.Int J Immunopathol Pharmacol. 2023;37:3946320231172881. [DOI] [PubMed] [PMC]
Halling A, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.J Am Acad Dermatol. 2021;84:139–47. [DOI] [PubMed]
Blunder S, Hermann-Kleiter N, Mahmuti R, Hermann M, Ortner D, Reider D, et al. Blocking of IL-4/IL-13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome.Exp Dermatol. 2025;34:e70113. [DOI] [PubMed]
Zanichelli A, Wuillemin WA, Aygören-Pürsün E, Banerji A, Busse PJ, Betschel SD, et al. Lanadelumab’s impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidence.Ann Allergy Asthma Immunol. 2025;135:560–9. [DOI] [PubMed]
